George Demetri D. et alii ex Danai Fabre American / Briegen et Women 'Center Cancri hospitalis referunt in aegris cum liposarcoma, in usum iriprine versus in tergum-treatment erat significantly melioravit salvos commoda super dacarbazine. Nam cum aegris liposarcoma, plurrimi maximus res est eligere iribrin curatio quod morbo vitiatam rationem habet effectum in stricto efficacia. (J Oncol Clin. Poema Online August XXX, MMXVII)
A previous Phase III Volume iudicium et curatio provectus ostendit quod in dacarbazine irribrin comparari potest significantly liposarcoma sive meliorem altiore salvos leiomyosarcoma (OS), in adversa reactiones sunt et facilia, expedita et potestate. Conducted subgroup analysis Inquisitores iam de situ iribulin in coetus et coetus dacarbazine, ea quidem mente, dumque explicamus ad proprietate et salutem pertinet TEXTUS.
Enrollment conditions: patient age ≥18 years; advanced or advanced liposarcoma that cannot be cured by surgery or radiotherapy; ECOG performance status score ≤2; previous chemotherapy regimens ≥2, including anthracycline. Patients were randomly divided into erebrin group (1.4 mg / m2, d1, 8) or dacarbazine group (850 mg / m2, 1000 mg / m2, or 1200 mg / m2, d1) in a 1: 1 ratio. 21 days is a cycle. Study endpoints include OS, progression-free survival (PFS), and safety.
Eventus ostendit quod group erat significantly liposarcoma OS in melius. Mediana OS in iribulin et coetus eius dacarbazine 15.6 8.4 menses et menses respectively (HR = 0.51, XCV% C * 95 0.35; P <I). Iribulin in coetus, aegris cum omni liposarcoma histological species et regiones in effectum OS melius aegris. Mediana PFS erebrin de aegris in coetus et coetus dacarbazine 0.75 mensibus, 001 mensibus eventum respicientia (HR = 2.9, XCV% C * 1.7 0.52: P = 95). Certe similis in adversis inter duos coetibus.
